tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Wiebe K et al. FK506 rescue therapy in lung transplantation. 1998 Transplant. Proc. pmid:9636613
Lipson DA et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. 1998 Transplant. Proc. pmid:9636612
McAlister VC et al. Cost of liver transplantation using tacrolimus. 1998 Transplant. Proc. pmid:9636611
Mueller AR et al. Influence of immunosuppression on patient outcome after liver transplantation. 1998 Transplant. Proc. pmid:9636608
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
Charco R et al. Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636605
Nakamura M et al. Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation. 1998 Transplant. Proc. pmid:9636600
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Lang M et al. Impact of immunosuppression in liver transplantation across a positive crossmatch. 1998 Transplant. Proc. pmid:9636595
Mueller AR et al. Does initial graft function influence the outcome after liver transplantation? 1998 Transplant. Proc. pmid:9636594
Cantarovich M et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. 1998 Transplant. Proc. pmid:9636592
Bekersky I et al. Bioequivalence of a new strength tacrolimus capsule under development. 1998 Transplant. Proc. pmid:9636591
Liu WT et al. In vitro generation of tacrolimus metabolites and their detection in whole blood. 1998 Transplant. Proc. pmid:9636590
Steinmueller T et al. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. 1998 Transplant. Proc. pmid:9636589
Klupp J et al. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. 1998 Transplant. Proc. pmid:9636585
Abe M et al. Successful prednisone withdrawal after living-related liver transplantation. 1998 Transplant. Proc. pmid:9636584
Langrehr JM et al. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. 1998 Transplant. Proc. pmid:9636583
Bilbao I et al. Experience with neoral cyclosporine through the oral route in liver transplantation. 1998 Transplant. Proc. pmid:9636580
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. 1998 Transplant. Proc. pmid:9636575